Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Cipla arm, Novartis...

    Cipla arm, Novartis enter agreement for Ultibro Breezhaler to treat COPD

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-22T09:45:44+05:30  |  Updated On 22 Sept 2019 9:45 AM IST
    Cipla arm, Novartis enter agreement for Ultibro Breezhaler to treat COPD

    This partnership will enable Cipla arm (Breathe Free Lanka) to facilitate easy access to Ultibro Breezhaler for patients in Sri Lanka to help them alleviate specific debilitating symptoms of Chronic Obstructive Pulmonary Disease (COPD). As part of this agreement, Novartis will be responsible for manufacturing Ultibro Breezhaler at its global facilities in line with its commitment to quality, effectiveness and safety.


    Colombo: A subsidiary of Cipla, Breathe Free Lanka Pvt Ltd (“Breathe Free Lanka”), recently announced a partnership with Novartis for the marketing and distribution of Novartis’ Ultibro Breezhaler.


    This partnership will enable Cipla arm (Breathe Free Lanka) to facilitate easy access to Ultibro Breezhaler for patients in Sri Lanka to help them alleviate specific debilitating symptoms of Chronic Obstructive Pulmonary Disease (COPD). As part of this agreement, Novartis will be responsible for manufacturing Ultibro Breezhaler at its global facilities in line with its commitment to quality, effectiveness and safety.


    This development is in line with Cipla’s aim of addressing unmet patient needs in respiratory and other therapy areas in Sri Lanka. The company has a strong record of focusing its efforts on improving healthcare and enhancing access to innovative medicines for improved disease management and better quality of life, especially for patients who currently do not have easy access to critical medicines.


    Also Read: Cipla, Stempeutics ink licensing deal for Stempeucel-DFU to treat a diabetic foot ulcer


    Commenting on the same, Nishant Saxena, CEO, International Business (Europe & Emerging Markets), Cipla said, “As market leaders with significant presence in the respiratory segment, we look forward to leveraging our marketing and distribution strengths in Sri Lanka to take this product to as many patients as possible in furtherance of our purpose of ‘Caring for Life’.”


    Celine Landie, Managing Director, Singapore & Asian Emerging Markets, Novartis said, “Our partnership with Cipla is aligned with the Novartis commitment to address the unmet medical needs of COPD patients and improving their quality of life by providing innovative medicines and devices.”


    Breathe Free Lanka Pvt Ltd, a wholly-owned subsidiary of Cipla, was born out of the vision of making quality medicines accessible to patients across Sri Lanka.


    Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. The company is a player in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments.

    breathe free lankaBreezhalerCeline LandieCiplacipla dealcipla novartis agreementCOPDNishant SaxenaNovartisnovartis dealpharmapharma newsmpharma news indiapulmonary diseaseUltibro

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok